ReviewBMC cancer2018
Primary cardiac myxofibrosarcoma: case report, literature review and pooled analysis.
Review in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Staged Cesarean and Cardiac Surgery for Recurrent Left Atrial Myxofibrosarcoma in Pregnancy.JACC. Case reports · 2026Article
- When Recurrent Myxoma Is Not a Myxoma: Reclassification and Recurrence in Cardiac Myxofibrosarcoma.JACC. Case reports · 2026Article
- Early recurrence of left atrial myxofibrosarcoma: A case report of a clinical and histopathologic challenge.Journal of cardiothoracic surgery · 2026Article
- Case report of an aggressive cardiac myxofibrosarcoma with rapid disease progression.European heart journal. Case reports · 2025Article
- An exceptional case of huge myxofibrosarcoma of the pericardium.Journal of surgical case reports · 2025Article
- Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review.Current treatment options in oncology · 2025Review
- Primary Cardiac Myxofibrosarcoma of the Left Atrium with Heterologous Elements Mimicking a Cardiac Myxoma.The American journal of case reports · 2025Article
- Primary Cardiac Myxofibrosarcoma: A Case Report.Surgical case reports · 2025Article
- A rare presentation of primary cardiac myxofibrosarcoma: Case report and literature review.Cancer reports (Hoboken, N.J.) · 2024Review
- Article
- Surgical resection of primary intracardiac sarcomas and outcomes: A review of case reports over 20 years.Indian journal of thoracic and cardiovascular surgery · 2024Review
- Primary cardiac myxofibrosarcoma of the left atrium and pericardium: a case report.Journal of cardiothoracic surgery · 2023Article
- The Role of Multimodality Imaging in the Diagnosis and Follow-Up of Malignant Primary Cardiac Tumors: Myxofibrosarcoma-A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2023Article
- A rare case of left atrial myxofibromyosarcoma.Radiology case reports · 2023Article
- Multiple cardiac myxofibrosarcomas with complete right pulmonary artery occlusion: a case report.Frontiers in oncology · 2023Article
- Myxofibrosarcoma or myxoma: malignant transformation or misdiagnosis.Indian journal of thoracic and cardiovascular surgery · 2022Article
- Myxofibrosarcoma or myxoma: malignant transformation or misdiagnosis.Indian journal of thoracic and cardiovascular surgery · 2022Article
- Cardiac myxofibrosarcoma: the diagnostic dilemma.Indian journal of thoracic and cardiovascular surgery · 2022Article
- Primary cardiac myxofibrosarcoma with osteoid differentiation mimicking a left atrial myxoma: A rare entity.Journal of cardiology cases · 2020Article
- Genetic aberrations and molecular biology of cardiac sarcoma.Therapeutic advances in medical oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPrimary cardiac myxofibrosarcoma is a very rare cardiac malignancy. The majority of publications are limited to case reports. No pooled analyses of primary cardiac myxofibrosarcoma cases are available. Little clinical features and outcome patterns are acknowledged. The purpose of this study is to identify the clinical characteristics and prognostic factors of primary cardiac myxofibrosarcoma. CASE PRESENTATION: A case report of primary cardiac myxofibrosarcoma was presented, and a review of English language literatures of primary cardiac myxofibrosarcomas were performed electronically. Demographics, clinicopathologic data, therapy and follow-up were summarized. The median survival time and the mean survival time were calculated by Kaplan-Meier method. Survival distribution and overall survival were figured by log-rank test and cox proportional hazards models. We present a case, and retrospectively analyzed additional 30 patients derived from 24 isolated articles. The cohort consisted of 18 male and 13 female patients. The age was 41.87 ± 17.89 years. Some common features were found in clinical presentations, pathologic features, treatments and outcome patterns of primary cardiac myxofibrosarcoma. There were special features in echocardiography, histological and immunohistochemical examinations, which should be considered in diagnosis of primary cardiac myxofibrosarcoma. The median survival time/mean survival time (MST) was 14/32.66 months. The median survival time/mean survival time (MST) was 14/32.66 months. Compared to the other groups, the following groups had shorter survival characteristics, including age ≥ 40 years (14/11.79 months), female (14/26.26 months), mass diameter ≥ 40 mm (14/14.64 months), high-grade (2/11.81 months), and no post-treatment (14/28.09 months). Statistical analyses revealed that primary cardiac myxofibrosarcomas were more likely to present with local recurrences and dismal metastases. Tumors ≥ 40 mm in size (P = 0.055, HR = 6.79) or with high-grade (P = 0.063, HR = 11.45) had significantly worse prognosis.
conclusionsPrimary cardiac myxofibrosarcomas were more likely to present with local recurrences and dismal metastases. Echocardiography, together with histological method should be considered in ordinary diagnosis. Tumors ≥ 40 mm in size or with high-grade had significantly worse prognosis, which should be early diagnosed and treated with rational surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.